We are excited to announce that Ebglyss (Lebrikizumab) is now approved in Saudi Arabia for the treatment of patients with moderate to severe Atopic Dermatitis (AD) aged 12 and above. With its unique IL-13 inhibition mechanism, Ebglyss Starts Strong, Lasts Long, and is Maintained Monthly, along with a favorable safety profile proven in clinical trials.
